LOGIN  |  REGISTER
C4 Therapeutics
Cue Biopharma

LifeStance Health to Present at the 7th Annual Bernstein Healthcare Services Disruptors Conference

September 21, 2023 | Last Trade: US$8.05 0.01 0.12

SCOTTSDALE, Ariz., Sept. 21, 2023 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, today announced that management will present at the upcoming 7th Annual Bernstein Healthcare Services Disruptors Conference, which will be hosted in New York City, NY.

Details of the presentation are as follows:
Presenter: Dave Bourdon, CFO
Date: Wednesday, October 4, 2023
Time: 8:30 a.m. (Eastern time)
Moderated by: Lance Wilkes

The presentation will be webcast live and will be available on the Events and Presentations section of the LifeStance Health Investor Relations website (https://investor.lifestance.com).  

A replay of the webcast will be available after the conclusion of the event and can be accessed on the LifeStance Health Investor Relations website.

About LifeStance Health

Founded in 2017, LifeStance (NASDAQ: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental health care. LifeStance employs approximately 6,100 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 34 states and approximately 600 centers. To learn more, please visit www.LifeStance.com.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page